Non-viral gene therapy solutions for tissue regeneration

Tissues undergo damage due to various factors like disease, injury, ageing and need to be repaired and regenerated. The body is unable to always repair and regenerate tissues. In such cases, an instruction and boost to the body would help in regeneration.

TherageniX uses proprietary technology to deliver genes which can instruct the body to produce relevant proteins or factors that help in tissue regeneration.

📢Click here to view the same video with scientific jargon.

Our Technology and Focus

TherageniX’s virus-free peptide-based technology uses plasmid DNA and engineered peptides to form nanocomplexes that deliver DNA cargo into hard-to-transduce cells. Peptides can be customized to improve transduction while the cargo can be modified to deliver a variety of therapeutic agents.

With bone being the second most transplanted tissue after blood – 4 million grafting procedures are performed annually, along with a projected 45% increase in surgeries by 2030,  there is a critical demand for more effective treatment options. Bone implants often fail due to rejection, infection, or inadequate regeneration. TherageniX aims to deliver regenerative factor genes, such as BMPs and VEGF, intra-operatively with autologous bone marrow cells to enhance regeneration and reduce donor site trauma.  Additionally, TherageniX’s product can be combined with existing biomaterials, increasing patient access to this innovative therapy.

TherageniX technology offers several key advantages over existing options

  • Enhanced safety
  • Higher versatility and lower costs
  • Elimination of waiting times
  • Accelerated pipeline expansion opportunities

News from TherageniX